摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(2-chloro-5-nitrophenyl)-2H-indazole | 1195072-99-1

中文名称
——
中文别名
——
英文名称
2-(2-chloro-5-nitrophenyl)-2H-indazole
英文别名
——
2-(2-chloro-5-nitrophenyl)-2H-indazole化学式
CAS
1195072-99-1
化学式
C13H8ClN3O2
mdl
——
分子量
273.678
InChiKey
ZCUZTCJMVVBMKJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.59
  • 重原子数:
    19.0
  • 可旋转键数:
    2.0
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    60.96
  • 氢给体数:
    0.0
  • 氢受体数:
    4.0

反应信息

  • 作为反应物:
    描述:
    参考文献:
    名称:
    GDC-0449—A potent inhibitor of the hedgehog pathway
    摘要:
    SAR for a wide variety of heterocyclic replacements for a benzimidazole led to the discovery of functionalized 2-pyridyl amides as novel inhibitors of the hedgehog pathway. The 2-pyridyl amides were optimized for potency, PK, and drug-like properties by modifications to the amide portion of the molecule resulting in 31 (GDC-0449). Amide 31 produced complete tumor regression at doses as low as 12.5 mg/kg BID in a medulloblastoma allograft mouse model that is wholly dependent on the Hh pathway for growth and is currently in human clinical trials, where it is initially being evaluated for the treatment of BCC. (C) 2009 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2009.08.049
  • 作为产物:
    参考文献:
    名称:
    GDC-0449—A potent inhibitor of the hedgehog pathway
    摘要:
    SAR for a wide variety of heterocyclic replacements for a benzimidazole led to the discovery of functionalized 2-pyridyl amides as novel inhibitors of the hedgehog pathway. The 2-pyridyl amides were optimized for potency, PK, and drug-like properties by modifications to the amide portion of the molecule resulting in 31 (GDC-0449). Amide 31 produced complete tumor regression at doses as low as 12.5 mg/kg BID in a medulloblastoma allograft mouse model that is wholly dependent on the Hh pathway for growth and is currently in human clinical trials, where it is initially being evaluated for the treatment of BCC. (C) 2009 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2009.08.049
点击查看最新优质反应信息